WAP
CYTO

Wealthcare Advisory Partners’s Altamira Therapeutics Ltd CYTO Stock Holding History

Wealthcare Advisory Partners’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13
Closed -$17K – 2001
2021
Q1 		$17K Buy
+13
New +$17.4K ﹤0.01% 1275

Other funds holding CYTO

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Wealthcare Advisory Partners's CYTO Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2021, closing a stake of 13 shares — an estimated $17K sold.

Wealthcare Advisory Partners first reported a position in CYTO in Q1 2021 and held it in 1 quarter. The position peaked at $17K in Q1 2021. 11 funds tracked by Wall St. Rank hold CYTO as of Q2 2021.

  • Wealthcare Advisory Partners reported no remaining Altamira Therapeutics Ltd position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 13 Altamira Therapeutics Ltd shares in Q2 2021, an estimated $17K.
  • Wealthcare Advisory Partners first reported a position in Altamira Therapeutics Ltd in Q1 2021 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Altamira Therapeutics Ltd position peaked at $17K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.